On August 13, 2020, Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced a $70 million Series C financing led by Novo Growth, the growth equity arm of Novo Holdings. Soleus Capital also joined the round, along with earlier investors Mayfield, Cota, and Agilent, bringing the company’s total funding to more than $120 million. To support Mission Bio’s rapid growth, the funds will scale its single-cell multi-omics technology to expand the company’s reach in more effective clinical trials for novel cancer treatments, as well as characterization for cell and gene therapy. The company’s Tapestri Platform is the first-ever single-cell multi-omics platform capable of detecting DNA and protein changes simultaneously from the same cell — a capability necessary for the development of more impactful precision therapies. 

The Wilson Sonsini Goodrich & Rosati team that represented Mission Bio in the transaction includes:

Corporate
Raj Judge
Jonathan Chan
Annie Giomi
Kexi Wang
Jasbir Bains 

For more information, please see Mission Bio's press release.